How Long Does Ketamine Stay in Your Urine?

After a single dose, ketamine itself typically clears from urine within about two to five days, but its breakdown products linger considerably longer. A secondary metabolite called dehydronorketamine has been confirmed in urine up to ten days after a single small oral dose, and in people who use ketamine regularly, traces can persist for months. The actual detection window depends heavily on the dose, how often you’ve used the drug, which testing method a lab employs, and your individual metabolism. That spread between “a few days” and “a few months” is enormous, and the reasons behind it matter if you’re a patient receiving therapeutic ketamine, someone facing a drug screen, or simply curious about how the body handles this unusual substance.

Detection After a Single Dose

The most precise data on single-dose detection comes from a study that gave six volunteers a 50-milligram oral dose of ketamine and then tracked their urine using a highly sensitive mass spectrometry method. Ketamine itself could be confirmed in urine for up to five days. Norketamine, the first breakdown product the liver produces, was detectable for up to six days. And dehydronorketamine, a secondary metabolite the body forms afterward, stuck around for up to ten days.¹ Those numbers came from a method sensitive enough to pick up ketamine at 0.03 nanograms per milliliter, which is far more sensitive than the screening tests used in most workplace or clinical drug panels.

A separate study looking at therapeutic ketamine use in children found a similarly wide range but with a twist: the detection window shifted dramatically depending on the analytical technique the lab used. One method picked up ketamine for only two days post-administration while detecting norketamine for up to fourteen days. A different method on the same urine samples found ketamine for up to eleven days but norketamine for only six.² The takeaway is that “how long” is inseparable from “tested how,” which is worth understanding before you take any single number as gospel.

Why the Testing Method Changes the Answer

Most routine drug screens use immunoassay technology, which is fast and cheap but works by recognizing the general chemical shape of a drug rather than identifying it precisely. Standard immunoassay panels often do not even include ketamine. When ketamine is tested for, the immunoassay cutoff is typically set at 1,000 nanograms per milliliter. At that threshold, a single recreational or therapeutic dose will usually fall below the detection limit within one to three days.

Confirmatory tests are a different story. Techniques like liquid chromatography with tandem mass spectrometry can detect ketamine at concentrations hundreds or thousands of times lower than immunoassay cutoffs. At those levels, the parent drug and its metabolites become visible for much longer. The study that tracked volunteers after a single 50-milligram dose used detection limits of 0.03 and 0.05 nanograms per milliliter for ketamine and norketamine respectively, which is why it could confirm traces out to five and six days.¹ If your concern is a standard employment drug screen, the window is shorter. If you’re facing a forensic investigation with lab-grade confirmation testing, the window stretches considerably.

The study comparing two different mass spectrometry methods on the same samples makes this even clearer. One approach (GC-MS-NCI) saw ketamine for only two days but caught norketamine for fourteen. The other (LC-MS-APCI) found ketamine for eleven days but norketamine for only six.² The difference comes down to what each method is best at detecting. This variability means a laboratory’s choice of equipment and cutoff values can make the difference between a positive and a negative result, even with identical urine.

Chronic Use Extends the Window Dramatically

Everything discussed so far applies to a single or occasional dose. If you’ve been using ketamine repeatedly over weeks or months, the math changes in a big way. The drug and its metabolites accumulate in body tissues and are released slowly, creating detection windows measured in weeks rather than days.

A case series of chronic ketamine users found urine samples remained positive for anywhere between 22 and 96 days after the last known dose. Peak detection periods reached 61 days for ketamine itself, 40 days for norketamine, and 96 days for dehydronorketamine, all measured with a sensitive cutoff of 1.0 nanogram per milliliter.³ That is more than three months of potential detectability for the longest-lasting metabolite. The same study noted large differences between individuals in how the ratios of ketamine to its metabolites shifted over time, suggesting that chronic exposure affects each person’s metabolism differently.

This prolonged clearance matters for anyone undergoing repeated ketamine infusions for depression or chronic pain, not just for recreational users. If you are receiving treatment every few weeks, ketamine metabolites may never fully clear between sessions, meaning a drug test at any point during your treatment series could come back positive. If you have an upcoming drug screen, discussing timing with your prescriber makes sense.

How Your Body Breaks Down Ketamine

Ketamine is processed almost entirely in the liver. The first and most important step is a reaction called N-demethylation, where a liver enzyme clips off a methyl group to produce norketamine. The enzyme primarily responsible for this is CYP3A4, with a smaller contribution from CYP2B6 and CYP2C9.⁴ Norketamine is itself pharmacologically active, meaning it still has some effect on the brain even after the parent drug has been transformed.

From norketamine, the liver produces several secondary metabolites. Dehydronorketamine forms through further oxidation, and additional hydroxylated and glucuronidated products are created to make the compounds water-soluble enough for the kidneys to flush out.⁵ This cascade explains why metabolites persist in urine long after the drug’s effects have worn off. The parent compound disappears fairly quickly, but the liver’s cleanup products keep trickling through the kidneys for days or weeks.

One practical consequence of this metabolic pathway: in urine, the concentration of norketamine actually tends to exceed the concentration of ketamine itself. Research measuring the ratio in urine found an average ketamine-to-norketamine ratio of about 0.64, meaning there is more metabolite present than parent drug.⁶ Labs that test only for ketamine and not for its metabolites are therefore working with a less sensitive marker. Tests that include norketamine or dehydronorketamine cast a wider and longer-lasting net.

Individual Factors That Speed Up or Slow Down Clearance

The speed at which your liver processes ketamine is not uniform across the population. Some people clear the drug two or three times faster than others, even when receiving the same dose. Several factors drive this variation.

Genetics play a measurable role. The CYP2B6 enzyme, one of the enzymes involved in converting ketamine to norketamine, comes in several genetic variants. People who carry a variant called CYP2B6*6 metabolize ketamine substantially more slowly. In a study of chronic pain patients, those with two copies of the *6 variant had a median plasma clearance of about 22 liters per hour, compared with roughly 68 liters per hour in patients with the normal variant, which is about a threefold difference.⁷ Slower clearance from the blood translates directly to longer presence in urine. Lab studies have confirmed that the CYP2B6*6 variant impairs both the enzyme’s ability to bind ketamine and its catalytic activity.⁸ Additional genetic variants of CYP2B6, along with variants in a helper protein called cytochrome P450 oxidoreductase, have also been shown to reduce N-demethylation activity.⁹

Age is another factor. The same study that found the CYP2B6*6 effect also identified age as a significant predictor of slower clearance in chronic pain patients.⁷ Liver enzyme activity tends to decline with age, so older adults should expect somewhat longer detection windows than younger ones.

Beyond genetics and age, other variables affect clearance in ways that are harder to quantify precisely. Body fat percentage matters because ketamine is lipophilic, meaning it dissolves readily into fatty tissue, which acts as a reservoir that slowly releases the drug back into the bloodstream. People with higher body fat percentages tend to have longer elimination tails. Liver health is critical, since almost all of the metabolism happens there. Conditions that impair liver function, from cirrhosis to concurrent use of other drugs that compete for the same enzymes, slow clearance. The route of administration also matters: intravenous ketamine hits the bloodstream all at once, while oral ketamine passes through the liver first and is partially metabolized before it ever reaches general circulation. Nasal sprays fall somewhere in between.

Hydration and urine output affect concentration but not total elimination time. Drinking a lot of water dilutes the urine, which can push concentrations below a test’s cutoff sooner, but drug testing labs check for dilution. If the creatinine concentration in your sample falls below roughly 20 milligrams per deciliter, the sample is typically flagged as dilute and may be rejected.¹⁰ Trying to flush your system with excessive water is not a reliable strategy and can backfire.

False Positives and Screening Pitfalls

If you have never used ketamine but a urine screen comes back positive for it, a false positive may be the explanation. Immunoassay screens work by reacting to molecular shapes, and some other medications share enough structural similarity with ketamine to trigger the test. Quetiapine, an antipsychotic prescribed for conditions like schizophrenia and bipolar disorder, has been documented to cause false-positive ketamine results on immunoassay screens. In at least two reported cases, patients taking quetiapine showed positive initial results that were later overturned by confirmatory testing.¹¹

This is why confirmatory testing exists. If an immunoassay comes back positive, the standard practice is to run the same sample through a more specific technique like gas chromatography or liquid chromatography-mass spectrometry, which can distinguish ketamine’s exact chemical identity from look-alike molecules. If you are taking quetiapine or any other medication and face a ketamine screen, it is worth informing the testing facility in advance so they can interpret the results appropriately. A positive immunoassay alone is never definitive proof of ketamine use.

What Ketamine Does to Your Bladder on Its Way Out

One reason ketamine’s presence in urine matters beyond drug testing is its potential to damage the urinary tract. A condition known as ketamine-induced cystitis is a recognized consequence of heavy or chronic use. The exact mechanism is still not fully understood, but the leading theory centers on ketamine and its metabolites directly irritating the bladder lining as they pass through.¹²

Ketamine metabolites can trigger severe inflammation of the urothelium (the inner lining of the bladder), damage to the barrier that normally keeps urine from seeping into deeper tissue, changes in the blood vessels of the bladder wall, increased oxidative stress, and eventually fibrosis, where the bladder wall stiffens with scar tissue.¹³ Symptoms typically include severe urinary urgency, frequent urination, pelvic pain, and sometimes blood in the urine. In advanced cases, the bladder can shrink to a fraction of its normal capacity.

This condition is overwhelmingly associated with frequent, heavy use rather than single therapeutic doses. But given that metabolites from chronic use can persist in urine for months, the bladder is exposed to potentially irritating compounds for far longer than the user might assume. Stopping ketamine use is the single most important step in managing the condition, though recovery of bladder function can be slow and is not always complete. For patients receiving repeated therapeutic ketamine treatments, awareness of early urinary symptoms is worth discussing with a provider, since catching the problem early offers the best chance of preserving bladder health.

Comparing Ketamine to Other Substances on Drug Panels

Ketamine occupies an unusual position in the drug-testing world. Unlike cannabis, amphetamines, opioids, cocaine, and benzodiazepines, ketamine is not part of the standard five-panel or ten-panel urine drug screens used in most employment and clinical settings. It has to be specifically requested or included on an expanded panel. This means that many people who have used ketamine therapeutically or recreationally will never encounter a test that looks for it at all.

When ketamine is included, its detection window after a single dose falls somewhere between the shorter-lived substances (cocaine metabolites are typically detectable for two to four days) and the longer-lived ones (cannabis metabolites can persist for weeks in regular users). What makes ketamine somewhat unusual is the outsized role of its metabolites in extending that window. While the parent compound clears within days, dehydronorketamine’s ten-day single-dose window and potentially months-long chronic-use window are longer than many people expect for a drug whose subjective effects last only an hour or two.

If you are receiving ketamine treatments for depression or pain and are subject to regular drug testing, the practical move is documentation. A prescription or records from a ketamine clinic provide a legitimate medical explanation. The metabolite pattern in your urine, particularly the ratio of ketamine to norketamine and the presence of dehydronorketamine, is consistent with therapeutic use and can be distinguished by an experienced toxicologist from patterns more suggestive of single large recreational doses, though the distinction is not always clear-cut. Having your treatment records available before a test is far simpler than trying to contest a positive result after the fact.